Medication info

Nesina Act Tablet 12.5/15 mg

Prescription medicationTabletExpired
Ingredient · strength
Alogliptin Benzoate›17mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Celltrion Pharm, Inc.
Appearance
Light yellow, bilaterally convex, round film-coated tablets
Packaging
28 tablets / carton
Approval status
Expired

MFDS item code 201404899 · Approved 2014.10.24

This product's status changed to Expired on 2024.05.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medicine is administered once daily, with or without food. Do not split the tablets. The recommended starting doses of this medicine (alogliptin/pioglitazone) are as follows. ● For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: Administer this medicine 25mg/15mg. ● For patients who do not achieve adequate glycemic control with metformin monotherapy: Administer this medicine 25mg/15mg. ● For patients who do not achieve adequate glycemic control with pioglitazone monotherapy: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● For patients who do not achieve adequate glycemic control with combination therapy of pioglitazone and metformin: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● Replacement of combination therapy with alogliptin and pioglitazone: When switching from combination therapy with alogliptin and pioglitazone to this medicine, start at the current doses of alogliptin and pioglitazone. This medicine may be increased to a maximum of 25mg/30mg once daily according to the glycemic response. When starting treatment with this medicine or increasing the dose, closely monitor the patient for adverse reactions associated with fluid retention observed with pioglitazone use (e.g., weight gain, edema, and signs and symptoms of congestive heart failure). Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50 mL/min): No dose adjustment is required. - Patients with moderate renal impairment (creatinine clearance ≥30~ <50 mL/min): Administer this medicine 12.5 mg/15 mg or 12.5 mg/30 mg once daily. - This medicine should not be administered to patients with severe renal impairment or end-stage renal disease. - Because dose adjustment may be necessary depending on renal function, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter.

Ingredients

Importer
Celltrion Pharm, Inc.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by combining alogliptin and pioglitazone. It is used as an adjunct to diet and exercise in patients, effectively improving blood sugar levels. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.

Dosage and Administration

Adult dosage

This medicine is administered once daily, with or without food. Do not split the tablets. The recommended starting doses of this medicine (alogliptin/pioglitazone) are as follows. ● For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: Administer this medicine 25mg/15mg. ● For patients who do not achieve adequate glycemic control with metformin monotherapy: Administer this medicine 25mg/15mg. ● For patients who do not achieve adequate glycemic control with pioglitazone monotherapy: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● For patients who do not achieve adequate glycemic control with combination therapy of pioglitazone and metformin: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● Replacement of combination therapy with alogliptin and pioglitazone: When switching from combination therapy with alogliptin and pioglitazone to this medicine, start at the current doses of alogliptin and pioglitazone. This medicine may be increased to a maximum of 25mg/30mg once daily according to the glycemic response. When starting treatment with this medicine or increasing the dose, closely monitor the patient for adverse reactions associated with fluid retention observed with pioglitazone use (e.g., weight gain, edema, and signs and symptoms of congestive heart failure). Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50 mL/min): No dose adjustment is required. - Patients with moderate renal impairment (creatinine clearance ≥30~ <50 mL/min): Administer this medicine 12.5 mg/15 mg or 12.5 mg/30 mg once daily. - This medicine should not be administered to patients with severe renal impairment or end-stage renal disease. - Because dose adjustment may be necessary depending on renal function, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter.

Precautions

This medication may put stress on the heart; therefore, it should not be used in patients with heart failure or symptoms of heart failure. While taking this medication, patients should be carefully monitored for sudden weight gain, shortness of breath, or swelling in the legs, which are symptoms of heart failure. If these symptoms occur, it is essential to consult a healthcare professional for appropriate treatment, and if necessary, discontinue or reduce the dose of this medication. This medication may cause fluid retention and worsen heart failure; therefore, patients with edema should be particularly cautious. Patients with active bladder cancer or a history of bladder cancer should not take this medication, and if hematuria or discomfort during urination occurs, they should inform their doctor immediately. Women who are pregnant or may become pregnant should not take this medication, and premenopausal women should take appropriate contraceptive measures while using this medication. Patients with severe liver or kidney dysfunction should also avoid this medication, and those with moderate to severe renal impairment should use it with caution. This medication may cause hypoglycemia; therefore, caution is required when used in combination with hypoglycemic agents such as insulin or sulfonylureas. If abnormalities in liver function, severe joint pain, skin rashes, or severe allergic reactions occur while taking this medication, consult a healthcare professional immediately. Elderly patients or those in poor nutritional status may be more sensitive to side effects; therefore, caution is needed. This medication may interact with other drugs; thus, if other medications are being taken, it is essential to inform the healthcare professional. Children should not use this medication as its safety and efficacy have not been established.

Side effects

Congestive heart failure, excessive and rapid weight changes, dyspnea, edema, fluid retention, edema, nasopharyngitis, lumbago, upper respiratory infection, influenza, hypoglycemia, headache, sinusitis, myalgia, pharyngitis, pancreatitis, hypersensitivity, serum sickness, tendinitis, fracture, costochondritis, leg fracture, upper limb fracture, spinal fracture, rhabdomyolysis, thyroid carcinoma, lung cancer, lung carcinoma, acute pancreatitis, diarrhea, gastric ulcer, exacerbation of gastritis, hemorrhagic gastric ulcer, appendicitis, worsening blood sugar levels, dyspnea, exacerbation of asthma, exacerbation of pneumonia, respiratory arrest, abscess, infection, wound defect, chest discomfort, generalized edema, generalized weakness, cirrhosis, cholelithiasis, acute kidney failure, kidney stones, renal dysfunction, myocardial infarction, angina, decreased appetite, cerebral infarction, transient ischemic attack, rupture, exacerbation of atrial fibrillation, dysphasia, hypothyroidism, nodular goiter, diarrhea, dyspepsia, constipation, gastritis, vomiting, cough, sputum disease, bronchitis, rhinitis, pharyngitis, chest pain, low back pain, hyperglycemia, hyperlipidemia, diabetic complications, worsening of diabetes, dyslipidemia, increased triglycerides, dizziness, vertigo, cerebral dysfunction, arthralgia, neck and shoulder pain, osteoarthritis, pruritus, conjunctivitis, glaucoma, macular degeneration, cataract, keratitis, retinopathy, retinal disorders, retinal diseases, cholelithiasis, abnormal liver function test of unspecified origin, cirrhosis, sclerosing cholangitis, fatty liver, increased AST, increased ALT, herpes zoster, depression, hypersensitivity, erectile dysfunction, insomnia, sleep disorder, prostate enlargement, benign prostatic hyperplasia, orthostatic hypotension, hypotension, tinnitus, acute hearing loss, Ménière's disease, ear disease of unspecified origin, coronary artery occlusion, exacerbation of angina, bradycardia, palpitations, atherosclerosis, tendon rupture, vesicular pemphigoid, macular edema, severe joint pain accompanied by disability

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air or humidity; therefore, it should be stored in a sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This storage method will safely maintain the medication's effectiveness.

Appearance and packaging

Appearance

Light yellow, bilaterally convex, round film-coated tablets

Package unit

28 tablets / carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.